NCT00407459View on ClinicalTrials.gov

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Mesothelioma
Interventions
DRUG

Bevacizumab, Pemetrexed, Carboplatin

"* Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks~* Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks~* Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"

Trial Locations (1)

20089

Istituto Clinico Humanitas, Rozzano

All Listed Sponsors
lead

Armando Santoro, MD

OTHER

NCT00407459 - Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter